Cuminaldehyde as the Major Component of Cuminum cyminum, a Natural Aldehyde with Inhibitory Effect on Alpha-Synuclein Fibrillation and Cytotoxicity

Journal of Food Science

Volumn 80, Issue 10, 2015, Pages H2336-H2345

  Morshedi, Dina ^a   Aliakbari, Farhang ^a   Tayaranian Marvian, Amir ^a   Fassihi, Afshin ^b   Pan Montojo, Francisco ^c,d   Pérez Sánchez, Horacio ^b  

^a NATIONAL INSTITUTE OF GENETIC ENGINEERING AND BIOTECHNOLOGY   (Iran)

^b CATHOLIC UNIVERSITY OF MURCIA   (Spain)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Technische Universität München Munich Cluster for Systems Neurology   (Germany)

Author keywords

Alpha synuclein; Antifibrillation; Baicalein; Cuminaldehyde; Cuminum cyminum; Essential oil

Indexed keywords

ALPHA SYNUCLEIN; BAICALEIN; BENZALDEHYDE DERIVATIVE; CUMINALDEHYDE; ESSENTIAL OIL; FLAVANONE DERIVATIVE; PLANT EXTRACT;

ANIMAL; CHEMISTRY; CUMINUM; DRUG EFFECTS; METABOLISM; PARKINSON DISEASE; PATHOPHYSIOLOGY; PC12 CELL LINE; PLANT SEED; PROTEIN CONFORMATION; RAT;

ALPHA-SYNUCLEIN; ANIMALS; BENZALDEHYDES; CUMINUM; FLAVANONES; OILS, VOLATILE; PARKINSON DISEASE; PC12 CELLS; PLANT EXTRACTS; PROTEIN CONFORMATION; RATS; SEEDS;

EID: 84943350064     PISSN: 00221147     EISSN: 17503841     Source Type: Journal    
DOI: 10.1111/1750-3841.13016     Document Type: Article

References (39)

1. Acharya S, Safaie BM, Wongkongkathep P, Ivanova MI, Attar A, Klarner FG, Schrader T, Loo JA, Bitan G, Lapidus LJ. 2014. Molecular basis for preventing alpha-synuclein aggregation by a molecular tweezer. J Biol Chem 289:10727-37.
2. Adams R. 2007. Mass spectra and structure of compounds. 4th ed. Identification of essential oil components by gas chromatography/mass spectorscopy (Carol Stream, Ill.: Allured Pub. Corp.). p 53-697.
3. Ahmad B, Lapidus LJ. 2012. Curcumin prevents aggregation in alpha-synuclein by increasing reconfiguration rate. J Biol Chem 287:9193-9.
4. Allahghadri T, Rasooli I, Owlia P, Nadooshan MJ, Ghazanfari T, Taghizadeh M, Astaneh SD. 2010. Antimicrobial property, antioxidant capacity, and cytotoxicity of essential oil from cumin produced in Iran. J Food Sci 75:H54-61.
5. Angot E, Steiner JA, Lema Tome CM, Ekstrom P, Mattsson B, Bjorklund A, Brundin P. 2012. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One 7:e39465.
6. Ban T, Goto Y. 2006. Direct observation of amyloid growth monitored by total internal reflection fluorescence microscopy. Methods Enzymol 413:91-102.
7. Breydo L, Wu JW, Uversky VN. 2012. Alpha-synuclein misfolding and Parkinson's disease. Biochim Biophys Acta 1822:261-85.
8. Burre J, Sharma M, Sudhof TC. 2015. Definition of a molecular pathway mediating alpha-synuclein neurotoxicity. J Neurosci 35:5221-32.
9. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. 2009. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106:13010-5.
10. Diociaiuti M, Macchia G, Paradisi S, Frank C, Camerini S, Chistolini P, Gaudiano MC, Petrucci TC, Malchiodi-Albedi F. 2014. Native metastable prefibrillar oligomers are the most neurotoxic species among amyloid aggregates. Biochim Biophys Acta 1842:1622-9.
11. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, Engemann S, Pastore A, Wanker EE. 2008. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 15:558-66.
12. Gambin Y, VanDelinder V, Ferreon AC, Lemke EA, Groisman A, Deniz AA. 2011. Visualizing a one-way protein encounter complex by ultrafast single-molecule mixing. Nat Methods 8:239-41.
13. Hillmer AS, Putcha P, Levin J, Hogen T, Hyman BT, Kretzschmar H, McLean PJ, Giese A. 2010. Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. Biochem Biophys Res Commun 391:461-6.
14. Hong DP, Fink AL, Uversky VN. 2008. Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J Mol Biol 383:214-23.
15. Huang C, Ren G, Zhou H, Wang CC. 2005. A new method for purification of recombinant human alpha-synuclein in Escherichia coli. Protein Expr Purif 42:173-7.
16. Karami OR, Khodaverdi M, Aliakbari F. 2010. Antibacterial Effect of Effective Compounds of Satureja hortensis and Thymus vulgaris Essential Oils against Erwinia amylovora. J Agr Sci Tech 12:35-45.
17. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-9.
18. Kelly SM, Jess TJ, Price NC. 2005. How to study proteins by circular dichroism. Biochim Biophys Acta 1751:119-39.
19. Lamberto GR, Binolfi A, Orcellet ML, Bertoncini CW, Zweckstetter M, Griesinger C, Fernandez CO. 2009. Structural and mechanistic basis behind the inhibitory interaction of PcTS on alpha-synuclein amyloid fibril formation. Proc Natl Acad Sci U S A 106:21057-62.
20. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT, Jr. 2002. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418:291.
21. Liu Y, Carver JA, Calabrese AN, Pukala TL. 2014. Gallic acid interacts with alpha-synuclein to prevent the structural collapse necessary for its aggregation. Biochim Biophys Acta 1844:1481-5.
22. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. 2012. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:949-53.
23. Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, Iwatsubo T, Hisanaga S, Goedert M, Hasegawa M. 2006. Small molecule inhibitors of alpha-synuclein filament assembly. Biochemistry 45:6085-94.
24. Maturana MG, Pinheiro AS, Souza TL, Follmer C. 2014. Unveiling the role of the pesticides paraquat and rotenone on alpha-synuclein fibrillation in vitro. Neurotoxicology 46C:35-43.
25. Meng X, Munishkina LA, Fink AL, Uversky VN. 2009. Molecular mechanisms underlying the flavonoid-induced inhibition of alpha-synuclein fibrillation. Biochemistry 48:8206-24.
26. Meng X, Munishkina LA, Fink AL, Uversky VN. 2010. Effects of Various Flavonoids on the alpha-Synuclein Fibrillation Process. Parkinsons Dis 2010:650794.
27. Morshedi D, Ebrahim-Habibi A, Moosavi-Movahedi AA, Nemat-Gorgani M. 2010. Chemical modification of lysine residues in lysozyme may dramatically influence its amyloid fibrillation. Biochim Biophys Acta 1804:714-22.
28. Morshedi D, Rezaei-Ghaleh N, Ebrahim-Habibi A, Ahmadian S, Nemat-Gorgani M. 2007. Inhibition of amyloid fibrillation of lysozyme by indole derivatives-possible mechanism of action. FEBS J 274:6415-25.
29. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, Funk RH. 2010. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 5:e8762.
30. Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O'Sullivan GA, Pal A, Said J, Marsico G, Verbavatz JM, Rodrigo-Angulo M, Gille G, Funk RH, Reichmann H. 2012. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2:898.
31. Prabhudesai S, Sinha S, Attar A, Kotagiri A, Fitzmaurice AG, Lakshmanan R, Ivanova MI, Loo JA, Klarner FG, Schrader T, Stahl M, Bitan G, Bronstein JM. 2012. A novel "molecular tweezer" inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo. Neurotherapeutics 9:464-76.
32. Rabiee A, Ebrahim-Habibi A, Navidpour L, Morshedi D, Ghasemi A, Sabbaghian M, Nemati-Lay M, Nemat-Gorgani M. 2011. Benzofuranone derivatives as effective small molecules related to insulin amyloid fibrillation: a structure-function study. Chem Biol Drug Des 78:659-66.
33. Singh PK, Kotia V, Ghosh D, Mohite GM, Kumar A, Maji SK. 2013. Curcumin modulates alpha-synuclein aggregation and toxicity. ACS Chem Neurosci 4:393-407.
34. Stefanis L. 2013. α-Synuclein in Parkinson's Disease. Cold Spring Harb Perspect Med 2:1-23.
35. Taebnia N, Morshedi D, Doostkam M, Yaghmaei S, Ali-Akbari F, Singh G, Arpanaei A, Adams R. 2015. The effect of mesoporous silica nanoparticles surface chemistry and concentration on the α-synuclein fibrillation. RSC Adv 5:60966-74.
36. Vilar M, Chou H, Maji SK, Riek-Loher D, Verel R, Manning G, Stahlberg H, Riek R. 2008. The fold of alpha-synuclein fibrils. Proc Natl Acad Sci 105:8637-42.
37. Wagner J, Ryazanov S, Leonov A, Levin J, Shi S, Schmidt F, Prix C, Pan-Montojo F, Bertsch U, Mitteregger-Kretzschmar G, Geissen M, Eiden M, Leidel F, Hirschberger T, Deeg AA, Krauth JJ, Zinth W, Tavan P, Pilger J, Zweckstetter M, Frank T, Bahr M, Weishaupt JH, Uhr M, Urlaub H, Teichmann U, Samwer M, Botzel K, Groschup M, Kretzschmar H, Griesinger C, Giese A. 2013. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol 125:795-813.
38. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T, Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, Riek R. 2011. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 108:4194-9.
39. Zhu M, Han S, Zhou F, Carter SA, Fink AL. 2004. Annular oligomeric amyloid intermediates observed by in situ atomic force microscopy. J Biol Chem 279:24452-9.